Progress toward inducing immunologic tolerance to factor VIII.
about
Current animal models of hemophilia: the state of the artHemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectorsLessons Learned from Animal Models of Inherited Bleeding Disorders.High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cellsInhibitors - cellular aspects and novel approaches for tolerance.Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.Polymeric synthetic nanoparticles for the induction of antigen-specific immunological toleranceEngineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cellsIntraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B.The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunityStrategies to target long-lived plasma cells for treating hemophilia A inhibitors.Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.In vivo induction of regulatory T cells for immune tolerance in hemophilia.Gene therapy for immune tolerance induction in hemophilia with inhibitors.Innovating immune tolerance induction for haemophilia.Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.Complexity of immune responses to AAV transgene products - Example of factor IX.Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo
P2860
Q28072423-AFF6FF42-4A21-4C3F-8F1A-315179439CAFQ28079890-0B9D3990-B376-44DA-A730-8561636F9B7CQ30409863-0F16850D-46E2-4894-8AC3-645911E84C4EQ30577011-EB4AC83F-46EB-46DB-9760-CE796F63A2D9Q33748093-7ABF3CCD-9E01-4422-B016-A13C174D480BQ34045763-9CFEFDF2-1C00-4B64-8A7E-CB0DF52EF021Q34137024-A8B2D8CC-A1DD-4247-81C1-636CA1C3126DQ34380850-92C24B8C-A272-4B8A-885C-269105F5B035Q34424570-49E27989-08B2-4F9A-A1FC-69641CDE6143Q34985424-B4406699-B1B0-4B2F-AC42-1A612D5BA20DQ35080090-763F9FC6-7570-41D6-915D-1497C4535631Q35348677-C4D1E4F2-23C5-4265-9217-81D10DE17147Q35399235-2FFC7408-CB9B-4F93-BAD4-586E5953A884Q36037525-E9600E86-C8E9-434F-9438-C18D8F951A32Q36675079-A1C94870-628F-4272-AC18-96020DDE7252Q36832899-A83E99F6-4133-489D-83A1-272AC989E745Q37690441-A4B07030-5D3F-4D9A-BB82-C2231A4B24B8Q38206855-F626F8C9-D50B-471E-BE7A-4A66CC8C2165Q38574966-2ABAA22E-8BCE-4AFE-85A0-551486D51E6FQ38803022-5375E112-33B6-4C52-98E4-D8C62FF85A41Q38894155-ADFE8311-A4CA-4ED0-B337-3CF53FF509FAQ38937408-274D8147-3E6E-4E0C-B349-A8327AEFC1F2Q38944642-BF85774F-AACE-4C93-B7F1-E90FBB7FBBDBQ39394803-11C9F862-4B4A-4EFF-8768-FB8A0D5D3009Q39398719-90727EDE-1DCC-4CD2-827C-76B89447913DQ39600375-C4F7A602-D515-409E-9DB1-3D79EB89C0FBQ42381250-4EFC3E04-6C89-4EA5-9E45-0A8ADF93D31CQ57150012-2A3970CF-50F1-4E88-9863-69718785422A
P2860
Progress toward inducing immunologic tolerance to factor VIII.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Progress toward inducing immunologic tolerance to factor VIII.
@en
type
label
Progress toward inducing immunologic tolerance to factor VIII.
@en
prefLabel
Progress toward inducing immunologic tolerance to factor VIII.
@en
P2093
P2860
P1433
P1476
Progress toward inducing immunologic tolerance to factor VIII.
@en
P2093
Carol H Miao
David W Scott
Kathleen P Pratt
P2860
P304
P356
10.1182/BLOOD-2013-01-478669
P407
P577
2013-03-15T00:00:00Z